Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901

Lung Cancer - Tập 111 - Trang 38-42 - 2017
Naoto Morikawa1, Akira Inoue2, Shunichi Sugawara3, Makoto Maemondo4, Toshiyuki Harada5, Masao Harada6, Yuka Fujita7, Terufumi Katoh8, Hiroshi Yokouchi9, Hiroshi Watanabe10, Kazuhiro Usui11, Toshiro Suzuki12, Jun Sakakibara-Konishi13, Hiroki Nagai14, Mariko Kanbe15, Toshihiro Nukiwa16
1Iwate Medical University School of Medicine, 9-1, Uchimaru, Morioka, Iwate, 020-8505, Japan
2Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan
3Sendai Kosei Hospital, 4-15, Hirosemachi, Sendai-shi Aoba-ku, Miyagi, 980-0873, Japan
4Miyagi Cancer Center, 47-1 Unodayama, Aijimashiode, Natori, Miyagi 981-1293, Japan
5Japan Community Health Care Organization Hokkaido Hospital, 8-3-18, 1jo, Nakanoshima, Kotohira, Sapporo, Hokkaido, 062-8618, Japan
6Hokkaido Cancer Center, 2-3-54, 4jo, Kikusui, Shiraishi, Sapporo, Hokkaido, 003-0804, Japan
7Asahikawa Medical Center, 7-4048, Hanasakicho, Asahikawa, Hokkaido, 070-8644, Japan
8Kanagawa Cancer Center, 2-3-2, Nakao, Asahi, Yokohama, Kanagawa, 241-8514, Japan
9Fukushima Medical University, 1Hikariga-oka, Fukushima, 960-1295, Japan
10Saka General Hospital, 16-5, Nishikicho, Shiogama, Miyagi, 985-0024, Japan
11NTT Medical Center Tokyo, 5-9-22, Higashigotanda, Shinagawa, Tokyo, 141-8625, Japan
12Iwate Prefectural Isawa Hospital, 61, Ryugababa, Mizusawa, Oshu, Iwate, 023-0864, Japan
13Hokkaido University, Kita 8, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-0808, Japan
14Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto 606-8501, Japan
15Senseki Hospital, 53-7, Akai-aza-dai, Higashimatsushima, Miyagi, 981-0501, Japan
16Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose-shi, Tokyo, 204-8533, Japan

Tài liệu tham khảo

Jemal, 2008, Cancer statistics, CA Cancer J. Clin., 58, 71, 10.3322/CA.2007.0010 Herbst, 2008, Lung cancer, N. Engl J. Med., 359, 1367, 10.1056/NEJMra0802714 Greenlee, 2000, Cancer statistics, CA Cancer J. Clin., 50, 7, 10.3322/canjclin.50.1.7 Noda, 2002, Japan Clinical Oncology Group, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer, N. Engl. J. Med., 346, 85, 10.1056/NEJMoa003034 Satouchi, 2014, Phase III study comparing Amrubicin plus cisplatin with Irinotecan plus cisplatin in the treatment of extensive-disease small-cell Lung cancer: JCOG 0509, J. Clin. Oncol., 32, 1262, 10.1200/JCO.2013.53.5153 National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: small cell lung cancer, version 2. http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf, 2017 (Accessed 17, March, 20). Okamoto, 2007, Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702, Br. J. Cancer, 97, 162, 10.1038/sj.bjc.6603810 Rossi, 2012, Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data, J. Clin. Oncol., 30, 1692, 10.1200/JCO.2011.40.4905 Hermes, 2008, Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial, J. Clin. Oncol., 26, 4261, 10.1200/JCO.2007.15.7545 Schmittel, 2011, Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group, A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer, Ann. Oncol., 22, 1798, 10.1093/annonc/mdq652 Ishimoto, 2015, Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: a phase I study, Respir. Investig., 53, 156, 10.1016/j.resinv.2015.02.006 Inoue, 2006, A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer, J. Thorac. Oncol., 1, 551, 10.1016/S1556-0864(15)30358-0 Inoue, 2010, A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: north Japan Lung Cancer Study Group Trial 0405, Ann. Oncol., 21, 800, 10.1093/annonc/mdp384 Lara, 2009, Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOG S0124, J. Clin. Oncol., 27, 2530, 10.1200/JCO.2008.20.1061 Hanna, 2006, Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer, J. Clin. Oncol., 24, 2038, 10.1200/JCO.2005.04.8595 Sun, 2016, Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer, BMC Cancer, 16, 265, 10.1186/s12885-016-2301-6 Ikeda, 2014, Nagasaki Thoracic Oncology Group, A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer, Cancer Chemother. Pharmacol., 74, 497, 10.1007/s00280-014-2527-4 Kawashima, 2014, Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: north Japan Lung Cancer Group Trial 0802, Respir. Investig., 52, 190, 10.1016/j.resinv.2013.12.005 Inoue, 2014, Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: north Japan Lung Cancer group study 0803, J. Thorac. Oncol., 9, 1805, 10.1097/JTO.0000000000000362 Shipley, 2012, Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): a phase II study of the Sarah Cannon Research Institute (SCRI), J. Clin. Oncol., 30, 7100, 10.1200/jco.2012.30.15_suppl.7100 Yoh, 2010, Severe interstitial lung disease associated with amrubicin treatment, J. Thorac. Oncol., 5, 1435, 10.1097/JTO.0b013e3181e369a8
Thông tin
Thông tin xuất bản

Lung Cancer

Tập 111

38-42

Thông tin tác giả